Last reviewed · How we verify
Omegaven
At a glance
| Generic name | Omegaven |
|---|---|
| Also known as | purified fish oil, omega-3 fatty acids, eicosapentaenoicacid (EPA), docosahexaenoicacid (DHA), dl-a- tocopherol (antioxidant) |
| Sponsor | Aalborg University Hospital |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Intravenous Fish Oil Based Lipid Emulsion to Enhance Recovery in High-Risk Cardiac Surgery Patients (PHASE2)
- Expanded Access of Omegaven IV Fat Emulsion to Infants and Children With PNALD
- Effect of Parenteral Nutrition With n-3 PUFAs on Patients With Intestinal Failure (NA)
- Safety and Tolerability of Intravenous Fish Oil Lipid Emulsion in Children Undergoing Hematopoietic Cell Transplantation (PHASE1)
- Safety Study to Evaluate the Occurrence of EFAD in Pediatric Patients With PNAC Who Require More Than Eight Weeks of Omegaven Treatment
- Cholestasis Reversal: Efficacy of IV Fish Oil (PHASE2, PHASE3)
- Intravenous Fat Emulsion Comprised of Fish Oil in the Treatment of Parenteral Nutrition Induced Liver Injury in Infants
- Compassionate Use of Omegaven® for the Treatment of Intestinal Failure Associated Liver Disease in Children
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Omegaven CI brief — competitive landscape report
- Omegaven updates RSS · CI watch RSS
- Aalborg University Hospital portfolio CI